Navigation Links
MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results
Date:5/12/2008

MOUNTAIN VIEW, Calif., May 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the first quarter ended March 31, 2008.

The net loss for the first quarter ended March 31, 2008 was $14.3 million compared with $6.7 million during the same period in 2007. As of March 31, 2008, MAP Pharmaceuticals had cash, cash equivalents and short-term investments of $81.1 million.

First Quarter Financial Results

Research and development expenses for the first quarter ended March 31, 2008 were $11.8 million compared to $4.5 million for the same period in 2007. The increase in research and development expenses for the first quarter of 2008 was primarily related to increases in clinical trial expenses, personnel expenses to support Phase 3 clinical programs related to MAP Pharmaceuticals' two lead product candidates, and the attainment of a milestone related to the UDB program.

Sales, general and administrative expenses for the first quarter ended March 31, 2008 were $3.1 million compared to $1.7 million for the same period in 2007. The increase in sales, general and administrative expenses for the first quarter of 2008 was primarily related to increases in personnel expenses, share-based compensation and professional services.

MAP Pharmaceuticals had cash, cash equivalents and short-term investments as of March 31, 2008 of $81.1 million, compared to $95.0 million as of December 31, 2007. In addition, for the first quarter ended March 31, 2008, non-cash share-based compensation and depreciation was approximately $1.1 million.

"We are pleased with the progress we have made during the first quarter," said Timothy S. Nelson, President and Chief Executive Officer of
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... Healthpointe ’s Cosmetic Laser Institute in Anaheim ... smooth state, and reduces the appearance of fine lines and wrinkles. , According to ... to instantly add volume to your cheek area to correct age-related volume loss in ...
(Date:7/28/2015)... ... ... Bipolar disorder is often associated with mood swings ranging from depressive lows ... World Health Organization (WHO) has reported that bipolar disorder affects about 60 million people ... United States has the highest lifetime rate of bipolar disorder at 4.4% affecting 14 ...
(Date:7/28/2015)... ... 28, 2015 , ... A new Taiwanese study suggests that ... in the general population. Surviving Mesothelioma has just posted an article detailing the ... Taiwan’s National Health Research Institutes and three Taiwanese universities evaluated the health records ...
(Date:7/28/2015)... ... ... A new study published by HealthDay News on June 24, 2015, entitled ... possible new treatment option for people living with fibromyalgia – hyperbaric oxygen therapy treatments ... per week, patients experienced a significant decrease in pain, fatigue, and other symptoms of ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... There has ... most people think of highways, bridges and railroads, often overlooked is the over ... our homes and buildings and into sewage treatment facilities. According to the American ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:"I Am Not I" Music Video Raises Bipolar Disorder Awareness 2Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 3
... premiere issue of an aging-focused newsletter deals with two ... care reform from the perspective of older minority ... The Gerontological Society of America (GSA), the country,s largest ... for this issue was provided by sanofi-aventis. Based ...
... antibodies that could block HIV, study finds , FRIDAY, ... of a major hurdle in efforts to develop an AIDs ... the immune system can produce B cells with the potential ... AIDS. But the immune system mistakenly perceives these cells as ...
... , , PASADENA, Calif., Dec. 18 ... Scouts of America (BSA), and with it comes an invitation to ... celebration is the BSA,s participation in the Tournament of Roses Parade, ... , "This is an incredibly exciting and important time for our ...
... , MINNEAPOLIS, Dec. 18 ... North Carolina and Tennessee are now offering H1N1 vaccinations ... necessary. The H1N1 vaccinations can be obtained at MinuteClinic ... outside the District of Columbia; in North Carolina in ...
... exploring another rite of passage when they get to ... level of maturity, some students may find less joy ... Alberta psychologists has found that emotionally mature students may ... counterparts. In a study on emotional experiences ...
... researchers from the University of Vigo, Rutgers University in ... United Kingdom, has developed "laser spinning", a novel method ... able to manufacture bioglass nanofibres, the bioactive glass used ... spinning makes it possible to produce glass nanofibres of ...
Cached Medicine News:Health News:Boy Scouts of America Launch 100th Year With Scouting Experience of a Lifetime 2Health News:Boy Scouts of America Launch 100th Year With Scouting Experience of a Lifetime 3Health News:CVS MinuteClinic Now Providing H1N1 Vaccinations On Demand at all Locations in Maryland, North Carolina and Tennessee 2Health News:CVS MinuteClinic Now Providing H1N1 Vaccinations On Demand at all Locations in Maryland, North Carolina and Tennessee 3Health News:Sex in university may be better for mature audiences: study 2
(Date:7/28/2015)... , July 28, 2015 ... new research report with market overview, trends, ... forecast, porter analysis, recent developments, competitive scenario ... Global Industry Insight: Human Insulin Market Development ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778) Explore more ...
(Date:7/28/2015)... LINCOLNSHIRE, Ill. , July 28, 2015 ... acumen on par with their levels of clinical excellence. ... (AACC) Annual Meeting & Clinical Lab Expo, Sysmex is ... deliver a comprehensive and intuitive ecosystem that will help ... four key areas, Sysmex aims to add even more ...
(Date:7/28/2015)... July 28, 2015 Rigel Pharmaceuticals, Inc. (Nasdaq: ... report its second quarter 2015 financial results after market ... management will follow the announcement with a live ... (1:30pm Pacific Time) to discuss the financial results. ... call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) ...
Breaking Medicine Technology:Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 3Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 4Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 5Sysmex Moves Beyond a Better Box 2Sysmex Moves Beyond a Better Box 3Sysmex Moves Beyond a Better Box 4Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results 2
Therapeutic Drug Calibrator Series...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
The AST method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma...
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
Medicine Products: